Innovative solutions
    for more effective diagnostics

Presentation

Products

Pathogens

Client Care

Science

IFU

Contact

Blog

Products

Carbapenemase-Producing Enterobacteriaceae (CPE)


Coris BioConcept
 has always been committed to developing new technologies and products so its customers can perform more rapidly and accurately the detection and identification of infectious agents.

To face the growing problem of antibiotic-resistant bacteria, we have developed a new family of tests under the brand name “RESIST”.

LOGO-RESIST-R•G-WBg

Carbapenemase-Producing Enterobacteriaceae (CPE) represent a major health concern and any diagnostic tool allowing to help their laboratory detection can improve patient’s safety. Until today, non-molecular confirmatory testings of the presence of carbapenemases of Class A (KPC) and B (VIM, IMP, NDM) have been available.

Coris has launched the OXA-48 K-SeT, the first rapid test for the detection of the OXA-48 family carbapenemase.

 

RESIST Range will be progressively available.

Resist Range - Carbapenemase Producing Enterobacteriaceae

 

This first worldwide unique rapid test, named OXA-48 K-SeT, is aimed at the detection in 15 minutes of OXA-48-like-producing Enterobacteriacae from culture colonies.
Coris BioConcept also launched the KPC K-SeT kit whose aim is the identification of Carbapenemase KPC in bacteria culture.

Contact us for more information

Want to discover more about this new kit ? Clic on the video below to see how it works !

Launch of new respiratory products

Coris BioConcept is proud and pleased to announce the launch of three new respiratory products!

Streptococcus group A

Beta-hemolytic group A Streptococcus is one of the main bacteria responsible for upper respiratory tract infections, including sore throats, pharyngitis and scarlet fever.
Early diagnosis and antibiotic treatment of infections with group A Streptococcus help to drastically reduce the severity of symptoms and the incidence of serious complications including acute glomerulonephritis, rheumatic fever and peritonsillar abscess.

The Strep A-Strip test detects the specific antigen of group A streptococci directly from throat swab specimens.

Contact us for more scientific or technical information regarding this product.

Or visit the Streptococcus group A page.

 

Legionella pneumophila

Legionnaires’ disease is a serious pneumonia mostly (90%) caused by Legionella pneumophila which includes several serotypes with serogroup 1 accounting for over 80% of all infections.
The Legionella K-SeT is a direct antigen test to detect the Legionella pneumophila serogroup 1 antigen in urine samples.

The sensitivity and specificity are 97.6% and 100% which makes this test a prompt and suitable diagnostic tool in legionellosis diagnosis.

Contact us for more scientific or technical information regarding this product.

Or visit the Legionella pneumophila page.

 

Influenza A & B viruses

Rapid and reliable diagnosis of influenza is essential for identification of contagious patients and effective patient management.

The Coris “Influ A+B K-SeT” shows high sensitivity (90.9% type A and 91.8% type B) and specificity (100% type A et 98.1% type B).
The use of this test for diagnosis of influenza disease should enhance patient health care by enabling rapid and appropriate use of antiviral treatments and lowering inappropriate use of preventive antibiotic treatment still often prescribed by mistake.

Contact us for more scientific or technical information regarding this product.

Or visit the Influenza A & B viruses page.

 

 

 

Coris BioConcept
www.corisbio.com

HAT test to detect sleeping sickness – Market authorization in DRC !

Sensitivity and specificity of HAT Sero-K-SeT, a rapid diagnostic test for serodiagnosis of sleeping sickness caused by Trypanosoma brucei gambiense: a case-control study

Summary

Background

Human African trypanosomiasis (HAT) is a life-threatening infection affecting rural populations in sub-Saharan Africa.

Large-scale population screening by antibody detection with the Card Agglutination Test for Trypanosomiasis (CATT)/Trypanosoma brucei (T b) gambiense helped reduce the number of reported cases of gambiense HAT to fewer than 10 000 in 2011.

Because low case numbers lead to decreased cost-effectiveness of such active screening, we aimed to assess diagnostic accuracy of a rapid serodiagnostic test (HAT Sero-K-SeT) applicable in primary health-care centres.

Authors:

Dr Philippe Büscher PhD, Pascal Mertens PhD, Thierry Leclipteux PhD, Quentin Gilleman MSc, Diane Jacquet, Dieudonné Mumba-Ngoyi PhD, Patient Pati Pyana Vet Dr, Marleen Boelaert PhD, Veerle Lejon PhD

 

 

The whole paper is available on the following page: Human-African-Trypanosomiasis/Sciences

HAT-K-SeT_Blanc_1

New Product : GastroVir K-SeT

This GastroVir K-SeT kit was developped for simultaneuous detection of two major viruses responsible for 50 to 70% of gastroenterological diseases: Rotavirus and Adenovirus – serotypes 40/41.

The detection requires a 15 minutes run time with only a few seconds of manual handling to collect the sample with the material provided in the kit.

Besides, a multi-centre validation has been performed on 1.201 sample and let to great results: the performances of the GastroVir K-SeT kit are similar to those of the strip format with a high sensitivity (>99%) and specificity (>99%).

 

GastroVir-K-SeT_2

 

Contact us for any other information regarding this new product !

 

NEW PRODUCT ! HAT – Rapid Detection Test for Sleeping Sickness

Human African trypanosomiasis

Human African trypanosomiasis (HAT), or sleeping sickness, is a life-threatening neglected tropical infection affecting rural populations in sub-Saharan Africa. In West and Central Africa, chronic trypanosomiasis is caused by Trypanosoma brucei gambiense infection.(1) Control of the disease has been facilitated by the use of the card agglutination test for trypanosomiasis, which is particularly suited for large-scale screening of the populations at risk.(2) With the steadily decreasing prevalence of trypanosomiasis, individual rapid diagnostic tests that can be used in primary health centers, that are stable at ambient temperatures, and that are highly specific have become a research priority.(1)

We developed two rapid diagnostic tests for trypanosomiasis caused by T. brucei gambienseinfection. The HAT Sero-Strip and HAT Sero-K-SeT tests detect trypanosome-specific antibodies and are, respectively, a dipstick and a lateral-flow device for testing blood (30 μl) or plasma (15 μl); both tests provide results in 15 minutes. The tests contain variant surface glycoproteins of the T. brucei gambiense variable antigen types LiTat 1.3 and LiTat 1.5.(3)

More information about HAT product

Evaluation of the test

The tests were evaluated with the use of plasma from 198 patients with trypanosomiasis that was confirmed on parasitologic analysis and from 99 local controls with neither clinical nor serologic evidence of the disease. The specimens were collected in the Democratic Republic of Congo (4) and obtained from the World Health Organization HAT Specimen Bank (www.who.int/trypanosomiasis_african/research/en). All specimens were tested with the use of immune trypanolysis, the reference test for detecting specific antibodies against T. brucei gambiense variable antigen types LiTat 1.3 and LiTat 1.5.(5) To evaluate the applicability of these tests when blood was used, samples of reconstituted blood were prepared by adding plasma from patients with trypanosomiasis or from local controls to sedimented blood cells from a healthy donor.

Results are summarized in Table 1. As compared with the immune trypanolysis test, the HAT Sero-Strip showed excellent sensitivity, with specificity being slightly lower when plasma was tested (P=0.05). When reconstituted blood was tested, the sensitivity and specificity of the HAT Sero-Strip did not differ significantly from the sensitivity and specificity of immune trypanolysis (P>0.05 for both comparisons); for the HAT Sero-K-SeT, the sensitivity was lower than that of immune trypanolysis (P=0.01), but the specificity was not significantly different (P=0.32).

If further evaluation in the field confirms their diagnostic accuracy, we believe that the HAT Sero-K-SeT and the HAT Sero-Strip, with an estimated price of less than $2.50 each, may become valuable tools in the control of trypanosomiasis.


Büscher P.
(Institute of Tropical Medecine), Gilleman Q. (Coris BioConcept), Lejon V. (Institute of Tropical Medecine)


References
:

1. Simarro PP, Jannin J, Cattand P. Eliminating human African trypanosomiasis: where do we stand and what comes next? PLoS Med 2008;5(2):e55.

2. Magnus E, Vervoort T, Van Meirvenne N. A card-agglutination test with stained trypanosomes (C.A.T.T.) for the serological diagnosis of T.b. gambiense trypanosomiasis. Ann Soc Belg Med Trop 1978;58:169-76.

3. Büscher P, Draelants E, Magnus E, Vervoort T, Van Meirvenne N. An experimental latex agglutination test for antibody detection in human African trypanosomiasis. Ann Soc Belg Med Trop 1991;71:267-73.

4. Amin DN, Rottenberg ME, Thomsen AR, et al. Expression and role of CXCL10 during the encephalitic stage of experimental and clinical African trypanosomiasis. J Infect Dis 2009;200: 1556-65.

5. Van Meirvenne N, Magnus E, Büscher P. Evaluation of variant specific trypanolysis tests for serodiagnosis of human infections with Trypanosoma brucei gambiense. Acta Trop 1995;60:189-99.

New kit for Clostridium difficile

Rapid diagnostic test for Clostridium difficile

New kit with strip device available by end of November

Reliability of GDH test is a prerequisite with two- and three-step algorithms for lab Diagnosis of Clostridium difficile. This new C. diff-Strip kit meets this requirement with very relevant performances. An evaluation carried out on 250 human stool specimens was compared to the bacterial culture test used for routine testing at a clinical laboratory (Belgium) and led to the following performances : reliability of 97.6%.

We’ll be pleased to present this new product during MEDICA trade show 2012. Do not hesitate to meet us there, booth 1F38 or to contact us from now at client.care@corisbio.com.

Best regards,

Coris BioConcept Team

Launch of our new product : Clostridium difficile

Clostridium difficile is one of the most prevalent nosocomial pathogen mainly affecting patients after antibiotic treatment. Toxinogenic strains of C. difficile cause infections from mild diarrhoea to pseudomembranous colitis, potentially leading to death. The tissue-damaging enterotoxin (Toxin A) and the cytotoxin (Toxin B) produced by toxinogenic strains of C.difficile are responsible for the disease.

Due to the lack of sensitivity of toxins A&B rapid diagnostic tests, recommended algorithms for testing for toxinogenic C. difficile infection require detection of the C. difficile GDH as antigenic marker in stool as a first step. This test should have the highest possible sensitivity to ensure that no infected patients are missed.

Coris BioConcept Clostridium K-SeT allows the specific detection of C.difficile‘s GDH in stool specimen. There is a 100% concordance for detection of GDH between the Clostridium K-SeT test and an ELISA assay.  Moreover, another study shows a 100% NPV regarding culture.  This evaluation has been conducted in a reference lab in Brussels and compared to a test regarded as the reference test in the EC and the US.

This study has shown that the Coris test performs better than the reference one. Results have been submitted at the ICAAC meeting in San Francisco this year.

Categories


Home   -   Site Map   -   Privacy Policy   -   Contact   -   FAQ                   All rights reserved CorisBioconcept SPRL 1996-2012©                           www.corisbio.com

Web traffic Optimisation
UniverSem

Design, Programming & hosting
Impact communication